Auxiliary components: starch corn, lactoses monohydrate, sucrose, povidone 25 000, starch corn prezhelatinizirovanny, magnesium stearate, macrogoal 6000, calcium carbonate, titanium dioxide, povidone 700 000, глицерол 85%, dye ferrous oxide red, dye ferrous oxide yellow, wax mountain glycolic, talc.

Indications to use

Miniziston's use 20 fy is shown for peroral contraception.

Contraindications

Diabetes mellitus with vascular complications;
Arterial and venous fibrinferments, including a thromboembolism of a pulmonary artery, a deep vein thrombosis, cerebrovascular disturbances, a myocardial infarction (including in the anamnesis);
Heavy or multiple factors of risk of arterial and venous thrombosis;
Tranzitorny ischemic disturbances of cerebral circulation, stenocardia and other pathologies preceding thrombosis (including the anamnesis);
Serious illness of a liver, including the anamnesis (before normalization of laboratory indicators of hepatic tests);
High-quality or malignant new growths of a liver (including the anamnesis);
Vaginal bleedings of an unspecified etiology;
The diagnosed hormonedependent malignant tumors of mammary glands, generative organs or suspicion on them;
Pregnancy or suspicion on it;
Breastfeeding period;
Hypersensitivity to drug components.

In case of decree pathologies and states against the background of Miniziston's use by the 20th fy contraception should be stopped immediately.

Route of administration and dosage

Pill is taken inside, washing down with enough water, it is always strict in at one time (established by each woman individually) on 1 piece a day.

Reception should be begun with the tablet corresponding to a day of the week and to continue in the order specified on packaging within 21 days. Then there comes the seven-day break in use for which 2-3 day menstrualnopodobny bleeding begins. Reception of tablets from the following blister needs to be begun at the scheduled time for the eighth day after reception of the last tablet from previous even if bleeding of cancellation did not end.

In the absence of hormonal contraception last month it is necessary to begin Miniziston's reception 20 fy in the first day of menstrual bleeding.

If use is begun from 2 to 5 day of a menstrual cycle, then during the first 7 days use of an additional barrier method of contraception is required.

Upon transition from other oral combined contraceptives reception is begun from the next day after reception of the last tablet from packaging of the previous drug, but not later than the eighth day after a break in reception (for the contraceptives containing 21 dragees) or after reception of the last inactive dragee (for the means containing 28 dragees in packaging).

Upon transition from gestagenny contraception it is possible to begin reception of tablets without interruption: after preliminary reception mini-saw – in any day, after injection forms – in day of the following injection, when using an implant – in day of its removal.

In all listed cases during the first 7 days of reception of tablets it is necessary to use barrier contraceptives in addition.

At abortion in the I trimester of pregnancy administration of drug can be begun immediately without additional methods of contraception.

After abortion in the II trimester or childbirth use is recommended to be begun during the period from 21 to 28 day. At later beginning of peroral contraception during the first 7 days it is necessary to use condoms in addition. If the woman after abortion in the II trimester or childbirth had a sexual contact, then it is necessary to begin administration of drug only after an exception of pregnancy or the first periods.

Efficiency of contraception is broken at untimely reception of Miniziston 20 fy. It is necessary to consider that function suppression гипоталамо - pituitary and ovarian system comes after 7 days of continuous administration of drug, and having rummaged in reception never has to exceed 7 days.

At delay till 12 o'clock (no more than 36 hours from the moment of reception of the previous tablet) reliability of contraception does not decrease therefore accidentally passed dose should be accepted at once as soon as remembered, and following – at the scheduled time.

If from the moment of alleged reception there passed more than 12 hours, there is a risk of decrease in reliability of contraception. At the specified delay on the first week of reception the pill should be taken at once as soon as remembered even if it is necessary to take 2 pill at the same time, further to continue drug use at the scheduled time and during the next 7 days to apply additional barrier methods of contraception. If the woman had a sexual contact during previous to the admission of week, there is a risk of approach of pregnancy.

The probability of approach of pregnancy increases at the repeated admission of tablets and if administration of drug is missed shortly before the put break in reception.

If accidental delay of the next tablet made more than 12 hours and happened on the second week of contraception, then drug should be accepted as soon as possible even if it is necessary to take 2 pill at the same time, further to continue use in the usual mode. On condition of regular reception of Miniziston 20 fy during the previous 7 days use of additional contraceptive measures is not required. If reception of several tablets is missed or disturbance of the mode of dosing within 7 days before reception delay took place, then during the next 7 days additional use of condom is required.

If the woman forgot to take a pill on the third week in time, and delay lasted more than 12 hours, then the probability of decrease in effect of drug increases because of approach of a seven-day break. In this situation for preservation of contraceptive effect it is recommended to choose one of options of further actions. If during the previous 7 days drug was accepted without disturbances, then further use of Miniziston 20 fy does not demand use of additional methods of contraception.

The first option assumes reception of the last passed tablet as soon as possible, at once, as soon as the woman remembers even if it will be reception of 2 tablets at the same time. Further it is possible to continue inclusion in usual time until the end of all tablets in the current blister and without interruption in use to begin the following blister. Menstrualnopodobny bleeding until the end of reception of tablets from the following blister can not come, but the probability of emergence of the smearing allocations and breakthrough bleedings is high.

The second option consists in premature interruption of reception of tablets from the current blister: it is necessary to take the put seven-day break, including day of the admission and to begin reception of tablets from the new blister. If bleeding of cancellation did not come in due time, it is necessary to be convinced of lack of pregnancy.

If in the next 3-4 hours after reception of a tablet there was vomiting, then absorption process, most likely, will be partial. In this case it is possible to take the corresponding pill from the new blister, without breaking the contraception mode, or to consider the pill taken to vomiting passed and to use recommendations for the passed drug dose.

To delay bleeding of cancellation it is necessary to start reception of tablets from the new blister without interruption and to continue use about desirable day, up to the last tablet. During this period emergence of the smearing bloody allocations or breakthrough uterine bleedings is possible. After a seven-day break reception is resumed in the usual mode.

That to change day of the beginning of periods the next day weeks it is necessary to reduce a break by the desirable number of days. It is necessary to consider at the same time that than the break, that a high probability of the smearing allocations and breakthrough bleedings during reception of the following blister is less.

Side effects

In rare instances against the background of Miniziston's reception 20 fy the following undesirable effects can appear:

Reproductive system: disturbances of vulval secretion;
Alimentary system: vomiting, nausea;
Nervous system: headache, change or deterioration in mood, migraine;
Endocrine system: morbidity and tension of mammary glands, increase in mammary glands, allocation of a secret from mammary glands, change of body weight, change of a libido;
Others: a liquid delay in an organism, bad portability of contact lenses, allergic reactions.

Sometimes – development of a hloazma, is more often at a hloazma of pregnant women in the anamnesis.

Special instructions

Miniziston's use 20 fy needs to be begun after the full all-medical examination directed to a mammology research of mammary glands, cytologic studying of cervical slime, an exception of pregnancy and disturbances of coagulant system of blood.

At long use of drug the woman has to undergo control testing at least 1 time a year.

Tablets do not protect from diseases which are transmitted sexually, including HIV infection (AIDS).

Before drug use women with risk factors are recommended to estimate carefully need of peroral contraception at potential threat to their health.

Effect of the combined peroral contraceptives increases the frequency of emergence of a thromboembolism, arterial and venous thromboses.

Thrombosis of hepatic and mezenterialny blood vessels, veins and arteries of kidneys and retina of eyes is diagnosed for the women accepting drug in extremely exceptional cases though the direct connection with the combined contraceptive is not proved.

To symptoms of venous or arterial thrombosis a sudden asthma, a unilateral scelalgia and/or hypostasis of a leg, an unexpected fit of coughing, a strong sharp stethalgia treats with irradiation in the left hand (or without it), dizziness, a severe long headache, increase in frequency and weight of migraine, a diplopia, sudden loss of sight (partial or full), the inarticulate speech, a collapse with a partial attack or without it, a sudden considerable anesthesia in one of parts of a body, weakness, an acute abdomen, motive disturbances. At emergence of any of the specified indispositions it is necessary to see a doctor immediately.

Can point out biochemical parameters tendency to thrombosis: deficit of antithrombin III, a protein of S, protein of C, a gipergomotsisteinemiya, resistance to the activated protein C, anti-phospholipidic antibodies (lupoid anticoagulant, antibodies to cardiolipin).

The factors promoting increase in risk of development of a thromboembolism, venous or arterial thrombosis: the family anamnesis (a venous or arterial thromboembolism at parents at young age, brothers or sisters), smoking (especially after 35 years and at a large number of cigarettes in days), a dislipoproteinemiya, obesity (the index of body weight exceeds 30 kg on 1 ^sq.m), arterial hypertension, fibrillation of auricles, diseases of valves of heart, a long immobilization, extensive operations, any surgical interventions standing, a severe injury, a puerperal period.

At genetic predisposition to thrombosis survey is required from the corresponding specialist.

It is necessary to stop Miniziston's use 20 fy in 4 weeks prior to planned operation and to resume reception after a full immobilization only in 2 weeks.

Disturbances of blood circulation are possible at patients with a diabetes mellitus, a hemolitic uraemic syndrome, a system lupus erythematosus, nonspecific ulcer colitis, a disease Krone, a sickemia.

Increase in frequency and expressiveness of migraine against the background of administration of drug is the basis for its immediate cancellation.

Diagnosis of development of cancer of neck of uterus and mammary gland against the background of prolonged use of the combined contraceptive drugs is slightly higher, in comparison with the women who are not accepting them. Nevertheless to exact interrelation between pathology and influence of drug it is not established.

There is a risk of development of the new growths of a liver which in some cases are followed by intra belly bleeding. The doctor has to consider it at differential diagnosis of patients with complaints to severe pains in a stomach, increase in a liver or symptoms of intra belly bleeding.

Administration of drug increases risk of emergence of pancreatitis in women with a gipertriglitseridemiya (including the family anamnesis).

If effect of drug causes steady, clinically significant increase in arterial pressure, its further use should be cancelled or continued in a combination with adequate hypotensive therapy.

At tendency to a hloazma it is necessary to avoid influence of direct sunshine or ultraviolet radiation.

When carrying out laboratory researches it is necessary to warn medical staff about Miniziston's reception 20 fy.

Adaptation of an organism to effect of drug lasts 3 cycles, during this period the smearing bloody allocations or breakthrough bleedings can be observed. In case of frequent repetition or development of these indispositions without the visible reasons after the established regular cycles the woman needs to undergo careful inspection for an exception of pregnancy or malignant tumors.

In the absence of cancellation bleeding in two cycles in a row it is impossible to begin reception of the following blister to a pregnancy existence exception.

Influence of drug on ability to control of vehicles and mechanisms is not established.

Medicinal interaction

At a concomitant use of barbiturates, Phenytoinum, Primidonum, rifampicin, carbamazepine, it is possible – a topiramata, griseofulvin, an okskarbazepin, a felbamat (the drugs inducing microsomal enzymes of a liver), and also tetracyclines and ampitsillin with Miniziston 20 fy decrease in reliability of contraception and development of breakthrough bleedings is possible. Therefore in the period of need of this combination and within 7 days after the termination of reception of the specified means it is recommended to use barrier contraceptives in addition.

The entire period of a combination to rifampicin and within 28 days after the termination of its reception it is necessary to apply barrier contraception in addition. At purpose of rifampicin some days before the termination of the blister, the new blister should be begun without usual seven-day break.